<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146562</url>
  </required_header>
  <id_info>
    <org_study_id>03-154</org_study_id>
    <nct_id>NCT00146562</nct_id>
  </id_info>
  <brief_title>Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer</brief_title>
  <official_title>A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harold J. Burstein, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lowell General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in
      supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell
      growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in
      chemotherapy recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will receive chemotherapy every 2 weeks for up to 8 cycles (spread out of
           approximately 16 weeks, total) of treatment. On the day of chemotherapy treatment
           patients may receive an injection of darbepoetin alfa in addition to chemotherapy if
           their red blood cell count is below normal levels.

        -  On the day after chemotherapy treatment, patients will receive an injection of
           pegfilgrastim. There is one pegfilgrastim shot given per treatment cycle, for a total of
           8 injections. Once the patient has finished chemotherapy and the last of the
           pegfilgrastim shots, their participation in this trial will be complete.

        -  While on this study the following procedures will be performed: a physical exam will be
           done every 2 weeks, vital signs will be done every 2 weeks, and blood tests every 2
           weeks.

        -  This study also involves a Quality of Life Questionnaire done at the beginning of study
           treatment, at 2 months, 4 months, 6 months, and 1 year after starting the study
           treatment.

        -  Patients will remain on this study unless they experience unacceptable side effects from
           any of the treatment drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the rate of febrile neutropenia in women treated with dose-dense adjuvant chemotherapy receiving pegfilgrastim every 2 weeks.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of RBC transfusion among patients treated with dose-dense adjuvant chemotherapy receiving darbepoetin every 2 weeks.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">109</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin Alfa</intervention_name>
    <description>Given day before chemotherapy of red blood cell count is below normal</description>
    <other_name>Aranesp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Given as an injection the day before chemotherapy for a total of 8 injections</description>
    <other_name>Neulasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed breast cancer clinical stage I, II or III
             disease. Patients must be deemed of sufficient risk for tumor or recurrence

          -  Patients may receive the defined adjuvant chemotherapy treatment either following
             definitive breast surgery or prior to definitive breast surgery

          -  18 years of age or older

          -  ECOG performance status 0 or 1

          -  ANC &gt; 1,500/uL

          -  Hemoglobin &gt; 9 g/dL

          -  Platelets &gt; 100,000/ul

          -  Total bilirubin less than or equal to ULN

          -  AST/ALT &lt; 1.5 x ULN

          -  Creatinine within normal institutional limits

          -  PT/PTT &lt; institutional upper limit of normal

          -  LVEF &gt; 50%

        Exclusion Criteria:

          -  Previous cytotoxic chemotherapy or therapeutic radiation therapy

          -  Pregnant or lactating women

          -  Receiving any other investigational agents

          -  Stage IV breast cancer

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to pegfilgrastim or darbepoetin

          -  Previous exposure to G-CSF or pegfilgrastim or to recombinant erythropoetin-related
             growth factors.

          -  On antibiotics within 72 hours of registration

          -  Patients with immune deficiency who are at increased risk of lethal infections when
             treated with marrow-suppressive therapy, or HIV-positive patients receiving
             anti-retroviral therapy

          -  Sickle cell disease

          -  Known positive antibody response to any erythropoietic agent

          -  Known hematologic diseases

          -  Known history of hyperviscosity syndrome

          -  Patients on lithium

          -  RBC transfusion within past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Burstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faulkner Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Cancer Center</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <zip>01960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Harold J. Burstein, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>G-CSF</keyword>
  <keyword>pegfilgrastim</keyword>
  <keyword>darbepoetin alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

